Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
BACKGROUND AND METHODS Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection… Expand
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
- S. Yusuf, B. Pitt, C. Davis, W. Hood, J. Cohn
- The New England journal of medicine
- 1 August 1991
BACKGROUND Patients with congestive heart failure have a high mortality rate and are also hospitalized frequently. We studied the effect of an angiotensin-converting-enzyme inhibitor, enalapril, on… Expand
Eplerenone in patients with systolic heart failure and mild symptoms.
BACKGROUND Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of… Expand
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
background Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a… Expand
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
BACKGROUND Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a… Expand
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Background— Heart failure has an annual mortality rate ranging from 5% to 75%. The purpose of the study was to develop and validate a multivariate risk model to predict 1-, 2-, and 3-year survival in… Expand
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
- B. Pitt, R. Segal, F. Martinez, G. Meurers, O. B. O. E. investigators
- The Lancet
- 15 March 1997
BACKGROUND To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme… Expand
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
- B. Pitt, P. Poole‐Wilson, R. Segal, F. Martinez, O. B. O. E. investigators
- The Lancet
- 6 May 2000
BACKGROUND The ELITE study showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an… Expand
Spironolactone for heart failure with preserved ejection fraction.
BACKGROUND Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in… Expand